Efficacy and Tolerability of Viloxazine Extended-Release for Attention-Deficit/Hyperactivity Disorder in Adolescents and Adults: A Systematic Review With Qualitative Synthesis of All Studies and Meta-Analysis of Adolescent Data.
Publication/Presentation Date
3-1-2026
Abstract
Viloxazine extended-release (ER) is a non-stimulant medication approved for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric and adult populations. While numerous randomized controlled trials (RCTs) have demonstrated its efficacy in young populations, evidence specific to adolescents remains limited, and even fewer data on adults exist. This systematic review and meta-analysis evaluates the efficacy and tolerability of viloxazine ER in adolescents and adults through a qualitative synthesis of all available studies and a meta-analysis of adolescent data. A literature search was conducted in January 2026 using PubMed, the Cochrane Library, Google Scholar, and ClinicalTrials.gov. Eligible studies included RCTs evaluating the efficacy of viloxazine ER in adolescent or adult populations diagnosed with ADHD according to the
Volume
18
Issue
3
First Page
105176
Last Page
105176
ISSN
2168-8184
Published In/Presented At
Chapman, S. R., Roberti, C., Abouafech, A., & Mueller, M. (2026). Efficacy and Tolerability of Viloxazine Extended-Release for Attention-Deficit/Hyperactivity Disorder in Adolescents and Adults: A Systematic Review With Qualitative Synthesis of All Studies and Meta-Analysis of Adolescent Data. Cureus, 18(3), e105176. https://doi.org/10.7759/cureus.105176
Disciplines
Medicine and Health Sciences
PubMedID
41978610
Department(s)
Medical Education
Document Type
Article